Daratumumab,Talquetamab,Teclistamab,Pomalidomide
janssen,genmab
['cart,(-cartitude)', 'teclistamab']
in bcma exposed/refractory mm (n=40), teclistamab sc shows a response rate 52.5%, mrd- 17.5% at 10-5 via ngs, crs ~70% (grade 1/2), 15/21 responders maintaining response at a median follow-up 11.8 months #cartsm #asco22 #asco22_szu #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm